TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BARD, JOEL, ARCH, ROBERT, ZHANG, JUN, BRAMS, PETER, REILLY, CIARA, MADER, MICHELLE, FINLAY, WILLIAM, ISHINO, TETSUYA, HUANG, HAICHUN, HENNING, KARLA, CUNNINGHAM, ORLA, DEVAUX, BRIGITTE
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions. La présente invention concerne des anticorps, ou des fragments de liaison à l'antigène associés, qui se lient spécifiquement au TL1A. L'invention concerne en outre un procédé d'obtention de tels anticorps et des acides nucléiques codant pour ces anticorps. L'invention concerne en outre des compostions et des méthodes thérapeutiques destinées à utiliser ces anticorps dans le traitement et/ou la prévention de maladies, troubles ou états pathologiques à médiation par le TL1A.